Now FDA approved for cervical dystonia

DAXXIFY® is the peptide-engineered, long-lasting neurotoxin for durable symptom control injection to injection.1,2*

Available — 2024
Stay Updated On Product Availability Read Press Release This link opens in a new tab

*Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with DAXXIFY® 250U. In patients that requested retreatment prior to the loss of ≥80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.2-3

Side portrait close up of a woman's neck

DAXXIFY® demonstrates durable symptom relief that extends beyond the current retreatment interval of 12 weeks.1,2,4-8*

Per the Phase 3 pivotal trial, DAXXIFY® is generally safe and well tolerated, with no serious treatment-related adverse events reported.1,2

Learn more about DAXXIFY® performance in the pivotal trial.

*Median duration of effect, defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with DAXXIFY® 250U. In patients that requested retreatment prior to the loss of ≥80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles 1 and 2 in the ASPEN OLS.2,3

DAXXIFY® is the only botulinum toxin engineered with cell-penetrating peptide technology.1,6-10

Graphic of Peptide

Proprietary peptide 3D image

Learn more about the unique DAXXIFY® formulation from:

Conor Gallagher, PhD

VP, Medical Affairs and Scientific Innovation
Image of Conor Gallagher, PhD

The ASPEN program

DAXXIFY® demonstrated impressive performance in the ASPEN-1 pivotal study and the ASPEN open-label study (OLS).2,3

Learn about the clinical development program.

Additional Clinical Information
Image of Vial of Daxxify product

Access for physicians and patients

Revance is committed to securing broad coverage for DAXXIFY® and will provide practice support to minimize the complexity associated with reimbursement.

Portrait of a patient